Seeking Alpha

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...
FOX8 Cleveland

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of ...
Healio

Early initiation of Kesimpta associated with lower rates of disability worsening in MS

Please provide your email address to receive an email when new articles are posted on . 80% of study participants remained free of disability-worsening events at 6 months. Cumulative event rates for 6 ...
The American Journal of Managed Care

Subcutaneous Ofatumumab Shows Reduced Injection Reactions in Multiple Sclerosis

New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis, but ...